Europe Pharmaceutical Market Size, Share & Trends Analysis Report By Product (Branded, Generic), By Type (Prescription, OTC), By Therapeutic Category, By Region, And Segment Forecasts, 2021 - 2028
This report can be delivered to the clients within 72 Business Hours
Europe Pharmaceutical Market Growth & Trends
The Europe pharmaceutical market size is expected to reach USD 432.12 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 5.4% from 2021 to 2028. The market is driven by an increasing prevalence of diseases, a growing elderly population, and the approval and launch of novel products in the European region.
Overall, the pharmaceutical market in Europe is dominated by branded drugs; however, the generic drugs segment is anticipated to grow at the fastest rate over the forecast period. Loss of patent protection of key pharmaceutical products and increasing government initiatives to adopt generic drugs for the treatment are some of the key factors likely to boost generics demand in the coming years.
The capitalization opportunity is high for generic manufacturers in the European market as governments from each region are forming plans to meet the population’s demand and lower healthcare-associated expenditure of the country. The expiration of patent exclusivities and the building need for cost-effective treatments are fueling the penetration of biosimilars and generics.
Novel molecule entry in this market typically takes 12-13 years and an investment of over USD 2.5 billion. In 2019, the total R&D expenditure on pharmaceutical R&D was USD 44,881.92 million. Increased competition from growing economies, such as China and Brazil, has accelerated the European economic investment in research to maintain its dominance in the market.
Improvements in healthcare infrastructure are promoting the adoption of novel pharmaceuticals. Furthermore, an increase in drug launches in Europe is projected to propel the market growth. For instance, in 2020, 62 drugs were approved in Europe and 97 medicines received marketing approval in European countries. The highest number of drug approvals were observed in the oncology segment.
Key pharmaceutical companies offer strong branded drugs in multiple therapeutic segments. Increasing R&D efforts, the growing adoption of novel therapies, and strategic collaborations are likely to boost the penetration of branded drugs. Strong pipeline products in different therapeutic areas are likely to fuel the growth of branded drugs in Europe.
Europe Pharmaceutical Market Report Highlights
Europe Pharmaceutical Market Growth & Trends
The Europe pharmaceutical market size is expected to reach USD 432.12 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 5.4% from 2021 to 2028. The market is driven by an increasing prevalence of diseases, a growing elderly population, and the approval and launch of novel products in the European region.
Overall, the pharmaceutical market in Europe is dominated by branded drugs; however, the generic drugs segment is anticipated to grow at the fastest rate over the forecast period. Loss of patent protection of key pharmaceutical products and increasing government initiatives to adopt generic drugs for the treatment are some of the key factors likely to boost generics demand in the coming years.
The capitalization opportunity is high for generic manufacturers in the European market as governments from each region are forming plans to meet the population’s demand and lower healthcare-associated expenditure of the country. The expiration of patent exclusivities and the building need for cost-effective treatments are fueling the penetration of biosimilars and generics.
Novel molecule entry in this market typically takes 12-13 years and an investment of over USD 2.5 billion. In 2019, the total R&D expenditure on pharmaceutical R&D was USD 44,881.92 million. Increased competition from growing economies, such as China and Brazil, has accelerated the European economic investment in research to maintain its dominance in the market.
Improvements in healthcare infrastructure are promoting the adoption of novel pharmaceuticals. Furthermore, an increase in drug launches in Europe is projected to propel the market growth. For instance, in 2020, 62 drugs were approved in Europe and 97 medicines received marketing approval in European countries. The highest number of drug approvals were observed in the oncology segment.
Key pharmaceutical companies offer strong branded drugs in multiple therapeutic segments. Increasing R&D efforts, the growing adoption of novel therapies, and strategic collaborations are likely to boost the penetration of branded drugs. Strong pipeline products in different therapeutic areas are likely to fuel the growth of branded drugs in Europe.
Europe Pharmaceutical Market Report Highlights
- By therapeutic category, the oncology segment is expected to grow at the fastest rate owing to the increasing prevalence of cancer along with the entry of novel molecules into the market
- Based on product, generic drugs are expected to emerge as the fastest-growing segment over the forecast period owing to the increased preference of the consumers for generic drugs due to their cost-effectiveness
- In terms of type, the prescription segment held the largest share in 2020 owing to the presence of the majority of pharmaceuticals in the prescription category
- Western Europe held the largest share in 2020 owing to the presence of countries with developed healthcare systems
- The preference of companies for contract manufacturing is rising in Europe due to the specialized nature of pharmaceutical products and reasonable production costs
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation & Scope
1.1.1 Product
1.1.2 Type
1.1.3 Therapeutic Category
1.1.4 Regional Scope
1.1.5 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.3.5.1 Data for primary interviews in North America
1.3.5.2 Data for primary interviews in Europe
1.3.5.3 Data for primary interviews in Asia Pacific
1.3.5.4 Data for primary interviews in Middle East and Africa
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 Objective
1.9.2 Objective
1.9.3 Objective
1.9.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
2.2 Segment Insights
2.3 Competitive Insights
CHAPTER 3 EUROPE PHARMACEUTICALS MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Penetration and Growth Prospect Mapping
3.3 User Perspective Analysis
3.3.1 Consumer behavior analysis
3.4 Regulatory Framework
3.5 Market Dynamics
3.5.1 Market driver analysis
3.5.1.1 Growing prevalence of diseases
3.5.1.2Growing geriatric population
3.5.1.3Approval and launch of new drugs
3.5.1.4 Increasing healthcare expenditure
3.5.1.5 Emergence of biologics and biologics
3.5.1.6 Entry of new technologies in supply chain and production
3.5.2 Market restraint analysis
3.5.2.1 Patent expirations and increasing generic penetration
3.5.2.2 Pricing pressure
3.5.2.3 Impact of COVID-19
3.5.2.4 Reduced demand for prescription medicines for common ailments
3.5.2.5 Adverse effects of drugs
3.5.2.6 Competition from complementary and alternative medicine
3.5.3 Industry challenges
3.5.3.1 Presence of ambiguous regulatory framework
3.6 Europe Pharmaceuticals Market Analysis Tools
3.6.1 Industry analysis - Porter’s
3.6.2 PESTLE Analysis
3.6.3 Major deals and strategic alliances analysis
3.6.3.1 New product launch
3.6.3.2 Mergers and acquisitions
3.6.3.3 Expansion
3.6.3.4 Partnerships
3.6.3.5 Marketing & promotions
3.6.4 Market entry strategies
CHAPTER 4 EUROPE PHARMACEUTICALS MARKET - SEGMENT ANALYSIS, BY PRODUCT, 2017 - 2028 (USD BILLION)
4.1 Definition and Scope
4.2 Product Market Share Analysis, 2020&2028
4.3 Segment Dashboard
4.4 Europe Pharmaceuticals Market, by Product, 2017 to 2028
4.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
4.5.1 Branded
4.5.1.1 Branded market estimates and forecast, 2017 - 2028 (USD Billion)
4.5.2 Generic
4.5.2.1 Generic market estimates and forecast, 2017 - 2028 (USD Billion)
CHAPTER 5 EUROPE PHARMACEUTICALS MARKET - SEGMENT ANALYSIS, BY TYPE, 2017 - 2028 (USD BILLION)
5.1 Definition and Scope
5.2 Type Market Share Analysis, 2020&2028
5.3 Segment Dashboard
5.4 Europe Pharmaceuticals Market, by Type, 2017 to 2028
5.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
5.5.1 OTC
5.5.1.1 OTC market estimates and forecast, 2017 - 2028 (USD Billion)
5.5.2 Prescription
5.5.2.1 Prescription market estimates and forecast, 2017 - 2028 (USD Billion)
CHAPTER 6 EUROPE PHARMACEUTICALS MARKET - SEGMENT ANALYSIS, BY THERAPEUTIC CATEGORY, 2017 - 2028 (USD BILLION)
6.1 Definition and Scope
6.2 Therapeutic Category Market Share Analysis, 2020&2028
6.3 Segment Dashboard
6.4 Europe Pharmaceuticals Market, by Therapeutic Category, 2017 to 2028
6.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
6.5.1 Oncology
6.5.1.1 Oncology market estimates and forecast, 2017 - 2028 (USD Billion)
6.5.2 Cardiovascular diseases
6.5.2.1 Cardiovascular diseases market estimates and forecast, 2017 - 2028 (USD Billion)
6.5.3 Anti-infectives
6.5.3.1 Anti-infectives market estimates and forecast, 2017 - 2028 (USD Billion)
6.5.4 Central Nervous System Disorders
6.5.4.1 Central nervous system disorders market estimates and forecast, 2017 - 2028 (USD Billion)
6.5.5 Metabolic Disorders
6.5.5.1 Metabolic disorders market estimates and forecast, 2017 - 2028 (USD Billion)
6.5.6 Gastrointestinal Disorders
6.5.6.1 Gastrointestinal disorders market estimates and forecast, 2017 - 2028 (USD Billion)
6.5.7 Respiratory Diseases
6.5.7.1 Respiratory diseases market estimates and forecast, 2017 - 2028 (USD Billion)
6.5.7 Other Disorders
6.5.7.1 Other Disorders market estimates and forecast, 2017 - 2028 (USD Billion)
CHAPTER 7 EUROPE PHARMACEUTICALS MARKET - SEGMENT ANALYSIS, BY REGION, 2017 - 2028 (USD BILLION)
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2020&2028
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 Regional Market Share and Leading Players, 2020
7.5.1 Western Europe
7.5.2 Central and Eastern Europe
7.5.3 Nordic Regions
7.5.4 Rest of Europe
7.6 SWOT Analysis
7.6.1 Western Europe
7.6.2 Central and Eastern Europe
7.6.3 Nordic Regions
7.6.4 Rest of Europe
7.7 Market Size, & Forecasts, Revenue and Trend Analysis, 2020 to 2028
7.7.1 Western Europe
7.7.1.1 Western Europe market estimates and forecast, 2017-2028 (USD Billion)
7.7.1.2 U.K.
7.7.1.2.1 U.K. Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.1.3 Germany
7.7.1.3.1 Germany Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.1.4 France
7.7.1.4.1 France Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.1.5 Spain
7.7.1.5.1 Spain Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.1.6 Italy
7.7.1.6.1 Italy Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.2 Central and Eastern Europe
7.7.2.1 Central and Eastern Europe market estimates and forecast, 2017-2028 (USD Billion)
7.7.2.2 Poland
7.7.2.2.1 Poland Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.2.3 Hungary
7.7.2.3.1 Hungary Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.2.4 Switzerland
7.7.2.4.1 Switzerland Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.3 Nordic Regions
7.7.3.1 Nordic regions market estimates and forecast estimates and forecast, 2017-2028 (USD Billion)
7.7.3.2 Denmark
7.7.3.2.1 Denmark Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.3.3 Finland
7.7.3.3.1 Finland Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.3.4 Norway
7.7.3.4.1 Norway Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.4 Rest of Europe
7.7.4.1 Rest of Europe market estimates and forecast estimates and forecast, 2017-2028 (USD Billion)
CHAPTER 8 COMPETITIVE LANDSCAPE
8.1 Recent Developments & Impact Analysis, by Key Market Participants
8.1.1 Ansoff matrix
8.1.2 Heat map analysis
8.2 Company Categorization
8.2.1 Innovators
8.2.2 Market Leaders
8.3 Vendor Landscape
8.3.1 List of key distributors and channel partners
8.3.2 Key customers
8.3.3 Key company market share analysis, 2020
8.4 Public Companies
8.4.1 Company market position analysis
8.4.2 Company Market Share, by region, 2020
8.4.3 Competitive Dashboard Analysis
8.4.3.1 Market Differentiators
8.5 Private Companies
8.5.1 List of key emerging companies
8.6 Company Profiles
8.6.1 F. Hoffmann-La Roche Ltd.
8.6.1.1 Company Overview
8.6.1.2 Financial Performance
8.6.1.3 Product benchmarking
8.6.1.4 Strategic initiatives
8.6.2 Bristol-Myers Squibb Company
8.6.2.1 Company overview
8.6.2.2 Financial Performance
8.6.2.3 Product benchmarking
8.6.2.4 Strategic initiatives
8.6.3 AstraZeneca plc
8.6.3.1 Company Overview
8.6.3.2 Financial Performance
8.6.3.3 Product Benchmarking
8.6.3.4 Strategic Initiatives
8.6.4 Novartis AG
8.6.4.1 Company Overview
8.6.4.2 Financial Performance
8.6.4.3 Product Benchmarking
8.6.4.4 Strategic Initiatives
8.6.5 Johnson & Johnson Services, Inc.
8.6.5.1 Company Overview
8.6.5.2 Financial Performance
8.6.5.3 Product Benchmarking
8.6.5.4 Strategic Initiatives
8.6.6 Gilead Sciences, Inc.
8.6.6.1 Company Overview
8.6.6.2 Financial Performance
8.6.6.3 Product Benchmarking
8.6.6.4 Strategic Initiatives
8.6.7 GlaxoSmithKline plc.
8.6.7.1 Company Overview
8.6.7.2 Financial Performance
8.6.7.3 Product Benchmarking
8.6.7.4 Strategic Initiatives
8.6.8 Merck & Co., Inc.
8.6.8.1 Company Overview
8.6.8.2 Financial Performance
8.6.8.3 Product Benchmarking
8.6.8.4 Strategic Initiatives
8.6.9 Pfizer Inc.
8.6.9.1 Company Overview
8.6.9.2 Financial Performance
8.6.9.3 Product Benchmarking
8.6.9.4 Strategic Initiatives
8.6.10 Sanofi
8.6.10.1 Company Overview
8.6.10.2 Financial Performance
8.6.10.3 Product Benchmarking
8.6.10.4 Strategic Initiatives
8.6.11 Boehringer Ingelheim GmbH
8.6.11.1 Company Overview
8.6.11.2 Financial Performance
8.6.11.3 Product Benchmarking
8.6.11.4 Strategic Initiatives
1.1 Market Segmentation & Scope
1.1.1 Product
1.1.2 Type
1.1.3 Therapeutic Category
1.1.4 Regional Scope
1.1.5 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.3.5.1 Data for primary interviews in North America
1.3.5.2 Data for primary interviews in Europe
1.3.5.3 Data for primary interviews in Asia Pacific
1.3.5.4 Data for primary interviews in Middle East and Africa
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 Objective
1.9.2 Objective
1.9.3 Objective
1.9.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
2.2 Segment Insights
2.3 Competitive Insights
CHAPTER 3 EUROPE PHARMACEUTICALS MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Penetration and Growth Prospect Mapping
3.3 User Perspective Analysis
3.3.1 Consumer behavior analysis
3.4 Regulatory Framework
3.5 Market Dynamics
3.5.1 Market driver analysis
3.5.1.1 Growing prevalence of diseases
3.5.1.2Growing geriatric population
3.5.1.3Approval and launch of new drugs
3.5.1.4 Increasing healthcare expenditure
3.5.1.5 Emergence of biologics and biologics
3.5.1.6 Entry of new technologies in supply chain and production
3.5.2 Market restraint analysis
3.5.2.1 Patent expirations and increasing generic penetration
3.5.2.2 Pricing pressure
3.5.2.3 Impact of COVID-19
3.5.2.4 Reduced demand for prescription medicines for common ailments
3.5.2.5 Adverse effects of drugs
3.5.2.6 Competition from complementary and alternative medicine
3.5.3 Industry challenges
3.5.3.1 Presence of ambiguous regulatory framework
3.6 Europe Pharmaceuticals Market Analysis Tools
3.6.1 Industry analysis - Porter’s
3.6.2 PESTLE Analysis
3.6.3 Major deals and strategic alliances analysis
3.6.3.1 New product launch
3.6.3.2 Mergers and acquisitions
3.6.3.3 Expansion
3.6.3.4 Partnerships
3.6.3.5 Marketing & promotions
3.6.4 Market entry strategies
CHAPTER 4 EUROPE PHARMACEUTICALS MARKET - SEGMENT ANALYSIS, BY PRODUCT, 2017 - 2028 (USD BILLION)
4.1 Definition and Scope
4.2 Product Market Share Analysis, 2020&2028
4.3 Segment Dashboard
4.4 Europe Pharmaceuticals Market, by Product, 2017 to 2028
4.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
4.5.1 Branded
4.5.1.1 Branded market estimates and forecast, 2017 - 2028 (USD Billion)
4.5.2 Generic
4.5.2.1 Generic market estimates and forecast, 2017 - 2028 (USD Billion)
CHAPTER 5 EUROPE PHARMACEUTICALS MARKET - SEGMENT ANALYSIS, BY TYPE, 2017 - 2028 (USD BILLION)
5.1 Definition and Scope
5.2 Type Market Share Analysis, 2020&2028
5.3 Segment Dashboard
5.4 Europe Pharmaceuticals Market, by Type, 2017 to 2028
5.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
5.5.1 OTC
5.5.1.1 OTC market estimates and forecast, 2017 - 2028 (USD Billion)
5.5.2 Prescription
5.5.2.1 Prescription market estimates and forecast, 2017 - 2028 (USD Billion)
CHAPTER 6 EUROPE PHARMACEUTICALS MARKET - SEGMENT ANALYSIS, BY THERAPEUTIC CATEGORY, 2017 - 2028 (USD BILLION)
6.1 Definition and Scope
6.2 Therapeutic Category Market Share Analysis, 2020&2028
6.3 Segment Dashboard
6.4 Europe Pharmaceuticals Market, by Therapeutic Category, 2017 to 2028
6.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
6.5.1 Oncology
6.5.1.1 Oncology market estimates and forecast, 2017 - 2028 (USD Billion)
6.5.2 Cardiovascular diseases
6.5.2.1 Cardiovascular diseases market estimates and forecast, 2017 - 2028 (USD Billion)
6.5.3 Anti-infectives
6.5.3.1 Anti-infectives market estimates and forecast, 2017 - 2028 (USD Billion)
6.5.4 Central Nervous System Disorders
6.5.4.1 Central nervous system disorders market estimates and forecast, 2017 - 2028 (USD Billion)
6.5.5 Metabolic Disorders
6.5.5.1 Metabolic disorders market estimates and forecast, 2017 - 2028 (USD Billion)
6.5.6 Gastrointestinal Disorders
6.5.6.1 Gastrointestinal disorders market estimates and forecast, 2017 - 2028 (USD Billion)
6.5.7 Respiratory Diseases
6.5.7.1 Respiratory diseases market estimates and forecast, 2017 - 2028 (USD Billion)
6.5.7 Other Disorders
6.5.7.1 Other Disorders market estimates and forecast, 2017 - 2028 (USD Billion)
CHAPTER 7 EUROPE PHARMACEUTICALS MARKET - SEGMENT ANALYSIS, BY REGION, 2017 - 2028 (USD BILLION)
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2020&2028
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 Regional Market Share and Leading Players, 2020
7.5.1 Western Europe
7.5.2 Central and Eastern Europe
7.5.3 Nordic Regions
7.5.4 Rest of Europe
7.6 SWOT Analysis
7.6.1 Western Europe
7.6.2 Central and Eastern Europe
7.6.3 Nordic Regions
7.6.4 Rest of Europe
7.7 Market Size, & Forecasts, Revenue and Trend Analysis, 2020 to 2028
7.7.1 Western Europe
7.7.1.1 Western Europe market estimates and forecast, 2017-2028 (USD Billion)
7.7.1.2 U.K.
7.7.1.2.1 U.K. Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.1.3 Germany
7.7.1.3.1 Germany Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.1.4 France
7.7.1.4.1 France Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.1.5 Spain
7.7.1.5.1 Spain Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.1.6 Italy
7.7.1.6.1 Italy Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.2 Central and Eastern Europe
7.7.2.1 Central and Eastern Europe market estimates and forecast, 2017-2028 (USD Billion)
7.7.2.2 Poland
7.7.2.2.1 Poland Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.2.3 Hungary
7.7.2.3.1 Hungary Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.2.4 Switzerland
7.7.2.4.1 Switzerland Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.3 Nordic Regions
7.7.3.1 Nordic regions market estimates and forecast estimates and forecast, 2017-2028 (USD Billion)
7.7.3.2 Denmark
7.7.3.2.1 Denmark Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.3.3 Finland
7.7.3.3.1 Finland Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.3.4 Norway
7.7.3.4.1 Norway Pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
7.7.4 Rest of Europe
7.7.4.1 Rest of Europe market estimates and forecast estimates and forecast, 2017-2028 (USD Billion)
CHAPTER 8 COMPETITIVE LANDSCAPE
8.1 Recent Developments & Impact Analysis, by Key Market Participants
8.1.1 Ansoff matrix
8.1.2 Heat map analysis
8.2 Company Categorization
8.2.1 Innovators
8.2.2 Market Leaders
8.3 Vendor Landscape
8.3.1 List of key distributors and channel partners
8.3.2 Key customers
8.3.3 Key company market share analysis, 2020
8.4 Public Companies
8.4.1 Company market position analysis
8.4.2 Company Market Share, by region, 2020
8.4.3 Competitive Dashboard Analysis
8.4.3.1 Market Differentiators
8.5 Private Companies
8.5.1 List of key emerging companies
8.6 Company Profiles
8.6.1 F. Hoffmann-La Roche Ltd.
8.6.1.1 Company Overview
8.6.1.2 Financial Performance
8.6.1.3 Product benchmarking
8.6.1.4 Strategic initiatives
8.6.2 Bristol-Myers Squibb Company
8.6.2.1 Company overview
8.6.2.2 Financial Performance
8.6.2.3 Product benchmarking
8.6.2.4 Strategic initiatives
8.6.3 AstraZeneca plc
8.6.3.1 Company Overview
8.6.3.2 Financial Performance
8.6.3.3 Product Benchmarking
8.6.3.4 Strategic Initiatives
8.6.4 Novartis AG
8.6.4.1 Company Overview
8.6.4.2 Financial Performance
8.6.4.3 Product Benchmarking
8.6.4.4 Strategic Initiatives
8.6.5 Johnson & Johnson Services, Inc.
8.6.5.1 Company Overview
8.6.5.2 Financial Performance
8.6.5.3 Product Benchmarking
8.6.5.4 Strategic Initiatives
8.6.6 Gilead Sciences, Inc.
8.6.6.1 Company Overview
8.6.6.2 Financial Performance
8.6.6.3 Product Benchmarking
8.6.6.4 Strategic Initiatives
8.6.7 GlaxoSmithKline plc.
8.6.7.1 Company Overview
8.6.7.2 Financial Performance
8.6.7.3 Product Benchmarking
8.6.7.4 Strategic Initiatives
8.6.8 Merck & Co., Inc.
8.6.8.1 Company Overview
8.6.8.2 Financial Performance
8.6.8.3 Product Benchmarking
8.6.8.4 Strategic Initiatives
8.6.9 Pfizer Inc.
8.6.9.1 Company Overview
8.6.9.2 Financial Performance
8.6.9.3 Product Benchmarking
8.6.9.4 Strategic Initiatives
8.6.10 Sanofi
8.6.10.1 Company Overview
8.6.10.2 Financial Performance
8.6.10.3 Product Benchmarking
8.6.10.4 Strategic Initiatives
8.6.11 Boehringer Ingelheim GmbH
8.6.11.1 Company Overview
8.6.11.2 Financial Performance
8.6.11.3 Product Benchmarking
8.6.11.4 Strategic Initiatives
LIST OF TABLES
TABLE 1 List of Secondary Sources
TABLE 2 List of Abbreviations
TABLE 3 Regulatory Framework
TABLE 4 Europe Pharmaceuticals Market, By Region, 2017 - 2028 (USD Billion)
TABLE 5 Europe Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 6 Europe Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 7 Europe Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 8 Western Europe Pharmaceuticals Market, By Country, 2017 - 2028 (USD Billion)
TABLE 9 Western Europe Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 10 Western Europe Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 11 Western Europe Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 12 U.K. Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 13 U.K. Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 14 U.K. Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 15 Germany Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 16 Germany Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 17 Germany Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 18 France Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 19 France Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 20 France Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 21 Spain Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 22 Spain Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 23 Spain Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 24 Italy Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 25 Italy Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 26 Italy Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 27 Central and Eastern Europe Pharmaceuticals Market, By Country, 2017 - 2028 (USD Billion)
TABLE 28 Central and Eastern Europe Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 29 Central and Eastern Europe Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 30 Central and Eastern Europe Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 31 Poland Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 32 Poland Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 33 Poland Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 34 Hungary Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 35 Hungary Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 36 Hungary Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 37 Switzerland Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 38 Switzerland Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 39 Switzerland Pharmaceuticals Market, By Application, 2017 - 2028 (USD Billion)
TABLE 40 Nordic Regions Pharmaceuticals Market, By Country, 2017 - 2028 (USD Billion)
TABLE 41 Nordic Regions Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 42 Nordic Regions Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 43 Nordic Regions Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 44 Denmark Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 45 Denmark Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 46 Denmark Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 47 Finland Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 48 Finland Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 49 Finland Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 50 Norway Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 51 Norway Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 52 Norway Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 53 Rest of Europe Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 54 Rest of Europe Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 55 Rest of Europe Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 1 List of Secondary Sources
TABLE 2 List of Abbreviations
TABLE 3 Regulatory Framework
TABLE 4 Europe Pharmaceuticals Market, By Region, 2017 - 2028 (USD Billion)
TABLE 5 Europe Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 6 Europe Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 7 Europe Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 8 Western Europe Pharmaceuticals Market, By Country, 2017 - 2028 (USD Billion)
TABLE 9 Western Europe Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 10 Western Europe Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 11 Western Europe Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 12 U.K. Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 13 U.K. Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 14 U.K. Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 15 Germany Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 16 Germany Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 17 Germany Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 18 France Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 19 France Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 20 France Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 21 Spain Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 22 Spain Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 23 Spain Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 24 Italy Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 25 Italy Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 26 Italy Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 27 Central and Eastern Europe Pharmaceuticals Market, By Country, 2017 - 2028 (USD Billion)
TABLE 28 Central and Eastern Europe Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 29 Central and Eastern Europe Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 30 Central and Eastern Europe Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 31 Poland Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 32 Poland Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 33 Poland Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 34 Hungary Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 35 Hungary Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 36 Hungary Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 37 Switzerland Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 38 Switzerland Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 39 Switzerland Pharmaceuticals Market, By Application, 2017 - 2028 (USD Billion)
TABLE 40 Nordic Regions Pharmaceuticals Market, By Country, 2017 - 2028 (USD Billion)
TABLE 41 Nordic Regions Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 42 Nordic Regions Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 43 Nordic Regions Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 44 Denmark Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 45 Denmark Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 46 Denmark Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 47 Finland Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 48 Finland Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 49 Finland Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 50 Norway Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 51 Norway Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 52 Norway Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
TABLE 53 Rest of Europe Pharmaceuticals Market, By Product, 2017 - 2028 (USD Billion)
TABLE 54 Rest of Europe Pharmaceuticals Market, By Type, 2017 - 2028 (USD Billion)
TABLE 55 Rest of Europe Pharmaceuticals Market, By Therapeutic Category, 2017 - 2028 (USD Billion)
LIST OF FIGURES
FIG. 1 Europe Pharmaceuticals market segmentation
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Primary research pattern
FIG. 5 Primary interviews in Europe
FIG. 6 Market research approaches
FIG. 7 Value-chain-based sizing & forecasting
FIG. 8 QFD modeling for market share assessment
FIG. 9 Market formulation & validation
FIG. 10 Europe pharmaceuticals market snapshot
FIG. 11 Segment Insights
FIG. 12 Strategy framework
FIG. 13 Penetration & growth prospect mapping
FIG. 14 Consumer behavior analysis
FIG. 15 Market driver relevance analysis (Current & future impact)
FIG. 16 Market restraint relevance analysis (Current & future impact)
FIG. 17 Porter’s five forces analysis
FIG. 18 PESTLE analysis
FIG. 19 Strategy mapping
FIG. 20 Europe pharmaceuticals market: Product movement analysis
FIG. 21 Product segment dashboard
FIG. 22 Europe pharmaceuticals market product outlook: Key takeaways
FIG. 23 Branded market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 24 Generic market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 25 Europe pharmaceuticals market: Type movement analysis
FIG. 26 Type segment dashboard
FIG. 27 OTC pharmaceuticals market type outlook: Key takeaways
FIG. 28 Prescription market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 29 Europe pharmaceuticals market: therapeutic category movement analysis
FIG. 30 Therapeutic category segment dashboard
FIG. 31 Europe pharmaceuticals market therapeutic category outlook: Key takeaways
FIG. 32 Oncology market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 33 Cardiovascular diseases market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 34 Anti-infectives market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 35 Central nervous system disorders market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 36 Metabolic disorders market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 37 Gastrointestinal disorders market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 38 Respiratory diseases estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 39 Other Disorders estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 40 Regional outlook, 2020&2028
FIG. 41 Regional market dashboard
FIG. 42 Regional marketplace: Key takeaways
FIG. 43 Western Europe market share and leading players, 2020
FIG. 44 Central and Eastern Europe market share and leading players, 2020
FIG. 45 Nordic regions market share and leading players, 2020
FIG. 46 Rest of Europe market share and leading players, 2020
FIG. 47 Western Europe
FIG. 48 Western Europe pharmaceuticals market, 2017 - 2028 (USD Billion)
FIG. 49 U.K.
FIG. 50 U.K. pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 51 Germany
FIG. 52 Germany pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 53 France
FIG. 54 France pharmaceuticals market, 2017 - 2028 (USD Billion)
FIG. 55 Spain
FIG. 56 Spain pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 57 Italy
FIG. 58 Italy pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 59 Central and Eastern Europe
FIG. 60 Central and Eastern Europe pharmaceuticals market estimates and forecast, 2017 - 2028(USD Billion)
FIG. 61 Poland
FIG. 62 Poland pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 63 Hungary
FIG. 64 Hungary pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 65 Switzerland
FIG. 66 Switzerland pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 67 Nordic Regions
FIG. 68 Nordic regions pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 69 Denmark
FIG. 70 Denmark pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 71 Finland
FIG. 72 Finland pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 73 Norway
FIG. 74 Norway Europe pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 75 Rest of Europe
FIG. 76 Rest of Europe pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 77 Ansoff Matrix
FIG. 78 Heat map analysis
FIG. 79 Company market share analysis
FIG. 80 Company market position analysis
FIG. 81 Company market share, by region, 2020
FIG. 82 Market differentiators
FIG. 1 Europe Pharmaceuticals market segmentation
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Primary research pattern
FIG. 5 Primary interviews in Europe
FIG. 6 Market research approaches
FIG. 7 Value-chain-based sizing & forecasting
FIG. 8 QFD modeling for market share assessment
FIG. 9 Market formulation & validation
FIG. 10 Europe pharmaceuticals market snapshot
FIG. 11 Segment Insights
FIG. 12 Strategy framework
FIG. 13 Penetration & growth prospect mapping
FIG. 14 Consumer behavior analysis
FIG. 15 Market driver relevance analysis (Current & future impact)
FIG. 16 Market restraint relevance analysis (Current & future impact)
FIG. 17 Porter’s five forces analysis
FIG. 18 PESTLE analysis
FIG. 19 Strategy mapping
FIG. 20 Europe pharmaceuticals market: Product movement analysis
FIG. 21 Product segment dashboard
FIG. 22 Europe pharmaceuticals market product outlook: Key takeaways
FIG. 23 Branded market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 24 Generic market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 25 Europe pharmaceuticals market: Type movement analysis
FIG. 26 Type segment dashboard
FIG. 27 OTC pharmaceuticals market type outlook: Key takeaways
FIG. 28 Prescription market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 29 Europe pharmaceuticals market: therapeutic category movement analysis
FIG. 30 Therapeutic category segment dashboard
FIG. 31 Europe pharmaceuticals market therapeutic category outlook: Key takeaways
FIG. 32 Oncology market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 33 Cardiovascular diseases market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 34 Anti-infectives market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 35 Central nervous system disorders market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 36 Metabolic disorders market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 37 Gastrointestinal disorders market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 38 Respiratory diseases estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 39 Other Disorders estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 40 Regional outlook, 2020&2028
FIG. 41 Regional market dashboard
FIG. 42 Regional marketplace: Key takeaways
FIG. 43 Western Europe market share and leading players, 2020
FIG. 44 Central and Eastern Europe market share and leading players, 2020
FIG. 45 Nordic regions market share and leading players, 2020
FIG. 46 Rest of Europe market share and leading players, 2020
FIG. 47 Western Europe
FIG. 48 Western Europe pharmaceuticals market, 2017 - 2028 (USD Billion)
FIG. 49 U.K.
FIG. 50 U.K. pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 51 Germany
FIG. 52 Germany pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 53 France
FIG. 54 France pharmaceuticals market, 2017 - 2028 (USD Billion)
FIG. 55 Spain
FIG. 56 Spain pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 57 Italy
FIG. 58 Italy pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 59 Central and Eastern Europe
FIG. 60 Central and Eastern Europe pharmaceuticals market estimates and forecast, 2017 - 2028(USD Billion)
FIG. 61 Poland
FIG. 62 Poland pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 63 Hungary
FIG. 64 Hungary pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 65 Switzerland
FIG. 66 Switzerland pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 67 Nordic Regions
FIG. 68 Nordic regions pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 69 Denmark
FIG. 70 Denmark pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 71 Finland
FIG. 72 Finland pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 73 Norway
FIG. 74 Norway Europe pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 75 Rest of Europe
FIG. 76 Rest of Europe pharmaceuticals market estimates and forecast, 2017 - 2028 (USD Billion)
FIG. 77 Ansoff Matrix
FIG. 78 Heat map analysis
FIG. 79 Company market share analysis
FIG. 80 Company market position analysis
FIG. 81 Company market share, by region, 2020
FIG. 82 Market differentiators
